If the FDA approves a drug for a neglected tropical disease, the company gets a voucher that accelerates review of another drug. This remains controversial.
The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results